Entrada Therapeutics
(NASDAQ) TRDA
Entrada Therapeutics Financials at a Glance
Market Cap
$268.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$5.74M
Net Income (TTM)
-$166.12M
EPS (TTM)
-$4.00
P/E Ratio
-1.73
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$6.95
Volume
380,492.066
Open
$7.41
Price
$6.95
Volume
380,492.066
Open
$7.41
Previous Close
$6.92
Daily Range
$6.73 - $7.44
52-Week Range
$4.93 - $16.45
Estimated Earnings Date
Aug 5, 2026
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$6.95
Volume
380,492.066
Open
$7.41
Previous Close
$6.92
Daily Range
$6.73 - $7.44
52-Week Range
$4.93 - $16.45
Estimated Earnings Date
Aug 5, 2026
TRDA News
TRDA: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Entrada Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
152
CEO
Dipal Doshi, MBA
Website
www.entradatx.comHeadquarters
Boston, MA 02210, US
TRDA Financials
Key Financial Metrics (TTM)
Gross Margin
-598.01%
Operating Margin
-3109.29%
Net Income Margin
-2895.05%
Return on Equity
-51.22%
Return on Capital
-43.69%
Return on Assets
-49.51%
Earnings Yield
-57.80%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$268.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
38.82M
Volume
380.49K
Avg. Volume
414.93K
Financials (TTM)
Gross Profit
-$34.31M
Operating Income
-$178.41M
EBITDA
-$164.87M
Operating Cash Flow
-$131.70M
Capital Expenditure
$59.00K
Free Cash Flow
-$131.64M
Cash & ST Invst.
$254.86M
Total Debt
$49.75M
Entrada Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$875.00K
-95.7%
Gross Profit
$70.00K
-99.7%
Gross Margin
8.00%
N/A
Market Cap
$268.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$1.47M
N/A
Employees
183
N/A
Net Income
-$39.72M
-128.9%
EBITDA
-$38.87M
-137.0%
Quarterly Fundamentals
Total Cash
$254.86M
-33.4%
Total Debt
$49.75M
-12.7%
Accounts Receivable
$2.29M
+11.9%
Inventory
$0.00
N/A
Long Term Debt
$45.47M
-9.9%
Short Term Debt
$4.28M
-34.2%
Return on Assets
-49.51%
N/A
Return on Invested Capital
-56.40%
N/A
Free Cash Flow
-$41.74M
-5.3%
Operating Cash Flow
-$41.70M
-8.3%